Results 161 to 170 of about 113,188 (264)

CD19-Negative Acute Lymphoblastic Leukemia (ALL): A Case Report and Review of Literature on a Rare Phenomenon De Novo and a Future Induced Struggle in Relapse. [PDF]

Int J Mol Sci
Arrabito M, Cannata E, Samperi P, Rosa M, Nigro LL.   +4 more
europepmc   +1 more source

Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

VIEW, EarlyView.
Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf, Yara Mashal, Afeefa Rao, Nasar Ata, Arun K. Iyer, Farhan Shah   +5 more
wiley   +1 more source

Allogeneic CD19 CAR T cells armed with an anti-rejection CD70 CAR overcome antigen escape and evade alloimmune responses. [PDF]

Nat Commun
Zhang K, Li Z, O'Dair MK, Qu D, Mealy AK, Nguyen D, Cheng HY, Huang D, Gopalakrishnan S, Roberts ZJ, Sommer C, Lauron EJ.   +11 more
europepmc   +1 more source

Angiogenesis‐associated immune genes as prognostic markers and predictors of immunotherapy response in pancreatic ductal adenocarcinoma

VIEW, EarlyView.
Pancreatic ductal adenocarcinoma exhibits marked angiogenic and immune heterogeneity. We identified 28 angiogenesis‐associated immune genes and developed a seven‐gene AIGScore model comprising FGF2, ADGRB3, MMP2, TYMP, VASH1, VEGFD, and ITGAV. A high AIGScore was associated with poor survival, an immunosuppressive tumor microenvironment, and reduced ...
Qing Chang, Qian Wang, Xiumei Jiang, Yongmei Yang, Ailin Qu   +4 more
wiley   +1 more source

Emerging therapeutic advances for immune thrombocytopenia: highlights from selected early‑phase and pivotal trials at the 2025 ASH annual meeting. [PDF]

Exp Hematol Oncol
Cao L, Wang Z, Xiang Q.
europepmc   +1 more source

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

Beyond malignancies: Clinical advancements of CAR T-cell in the treatment of autoimmune diseases. [PDF]

Intractable Rare Dis Res
Fang X, Wei R, Zhu W, Hu Y, Liang H.
europepmc   +1 more source

Epstein‐Barr virus as a driver of lupus: Rethinking triggers in autoimmunity

Rheumatology &Autoimmunity, EarlyView.
Jiekai Tan, Fanlei Hu, Chuanhui Xu
wiley   +1 more source

Autosomal Dominant Hyper‐IgE Syndrome Patients Retain IL10‐Producing preTh17‐Cells That Are Activated by Opportunistic Pathogens and Support IgE Production

Allergy, EarlyView.
IL‐10 producing CCR6+Th‐cells are central memory T‐cells that express ROR‐γt and differentiate to Th17‐cells via an autocrine loop of STAT3‐activating cytokines (preTh17). STAT3‐deficient AD‐HIES patients lack Th17‐ and Tfh17‐cells but retain preTh17‐ and Th1/17‐cells.
Giorgia Moschetti, Chiara Vasco, Francesca Clemente, Paola Larghi, Sara Maioli, Edoardo Scarpa, Elena Carelli, Nadia Pulvirenti, Maria Lucia Sarnicola, Mariacristina Crosti, Manal Bel Imam, Willem van de Veen, Loris Rizzello, Sergio Abrignani, Lucia A. Baselli, Rosa Maria Dellepiane, Maria Carrabba, Giovanna Fabio, Jens Geginat   +18 more
wiley   +1 more source